Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium

Structural and functional features of central nervous system lymphatic vessels

(2015) Antoine Louveau et al.   NATURE

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

(2014) Roger Stupp et al.   LANCET ONCOLOGY

Trial Watch

(2014) Fernando Aranda et al.   OncoImmunology

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

(2013) H. E. Kohrt et al.   BLOOD

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab

(2013) Jeffrey S. Weber et al.   CANCER

Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion

(2013) Sara Fritzell et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas

(2013) Jing Zeng et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability

(2013) D. A. Schaer et al.   Cancer Immunology Research

Ipilimumab and radiation therapy for melanoma brain metastases

(2013) Ann W. Silk et al.   Cancer Medicine

Modulation of GITR for cancer immunotherapy

(2012) David A Schaer et al.   CURRENT OPINION IN IMMUNOLOGY

Sequential Immunotherapy by Vaccination With GM-CSF–expressing Glioma Cells and CTLA-4 Blockade Effectively Treats Established Murine Intracranial Tumors

(2012) Pankaj Agarwalla et al.   JOURNAL OF IMMUNOTHERAPY

The role of STAT3 activation in modulating the immune microenvironment of GBM

(2012) Alfred P. See et al.   JOURNAL OF NEURO-ONCOLOGY

Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?

(2012) Shota Tanaka et al.   Nature Reviews Clinical Oncology

Potential Role for STAT3 Inhibitors in Glioblastoma

(2012) Christopher Jackson et al.   NEUROSURGERY CLINICS OF NORTH AMERICA

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation

(2012) N. Patsoukis et al.   Science Signaling

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

(2011) Q. Zhou et al.   BLOOD

Adult glioblastoma multiforme survival in the temozolomide era: A population-based analysis of Surveillance, Epidemiology, and End Results registries

(2011) Amy S. Darefsky et al.   CANCER

An immune-active tumor microenvironment favors clinical response to ipilimumab

(2011) Rui-Ru Ji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

Glucocorticoid-induced TNF receptor-triggered T cells are key modulators for survival/death of neural stem/progenitor cells induced by ischemic stroke

(2011) M Takata et al.   CELL DEATH AND DIFFERENTIATION

Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide

(2011) Stuart A. Grossman et al.   CLINICAL CANCER RESEARCH

Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family

(2011) Hélène Bour-Jordan et al.   IMMUNOLOGICAL REVIEWS

Tumor-Infiltrating Programmed Death Receptor-1+ Dendritic Cells Mediate Immune Suppression in Ovarian Cancer

(2011) J. Krempski et al.   JOURNAL OF IMMUNOLOGY

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4

(2011) O. S. Qureshi et al.   SCIENCE

Emerging Tim-3 functions in antimicrobial and tumor immunity

(2011) Kaori Sakuishi et al.   TRENDS IN IMMUNOLOGY

Activating and inhibitory receptors of natural killer cells

(2010) Hollie J Pegram et al.   IMMUNOLOGY AND CELL BIOLOGY

Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity

(2010) Rachel H. McMahan et al.   JOURNAL OF CLINICAL INVESTIGATION

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients

(2010) Julien Fourcade et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

(2010) Kaori Sakuishi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Tim-3/Galectin-9 Pathway: Regulation of Th1 Immunity through Promotion of CD11b+Ly-6G+ Myeloid Cells

(2010) V. Dardalhon et al.   JOURNAL OF IMMUNOLOGY

Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions

(2010) Tony Avril et al.   JOURNAL OF NEUROIMMUNOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation

(2010) Adam D. Cohen et al.   PLoS One

Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection

(2010) H.-T. Jin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation

(2009) J. Yu et al.   BLOOD

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells

(2009) F. Romagne et al.   BLOOD

Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model

(2009) Claire Banissi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody

(2009) M. Z. Dewan et al.   CLINICAL CANCER RESEARCH

CD28 and CTLA-4 coreceptor expression and signal transduction

(2009) Christopher E. Rudd et al.   IMMUNOLOGICAL REVIEWS

Combination approaches to immunotherapy: the radiotherapy example

(2009) Michael J Gough et al.   Immunotherapy

Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1

(2009) Dong-Ming Kuang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Negative Immune Regulator Tim-3 Is Overexpressed on T Cells in Hepatitis C Virus Infection and Its Blockade Rescues Dysfunctional CD4+ and CD8+ T Cells

(2009) L. Golden-Mason et al.   JOURNAL OF VIROLOGY

Immunotherapy Combined with Chemotherapy in the Treatment of Tumors

(2009) James L. Frazier et al.   NEUROSURGERY CLINICS OF NORTH AMERICA

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors

(2008) Joannes F.M. Jacobs et al.   NEURO-ONCOLOGY

HLA alleles determine differences in human natural killer cell responsiveness and potency

(2008) S. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation

(2007) Loredana Ruggeri et al.   BLOOD CELLS MOLECULES AND DISEASES

CTLA-4 disrupts ZAP70 microcluster formation with reduced T cell/APC dwell times and calcium mobilization

(2007) Helga Schneider et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study

(2007) Amy B. Heimberger et al.   NEURO-ONCOLOGY